The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy
where T lymphocytes are engineered with synthetic receptors known as chimeric antigen …

The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid
malignancies provided proof-of-principle for exploiting the immune system therapeutically …

Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic
modality pursued at an increasing number of medical centers. This immunotherapeutic …

Targeting T cell malignancies using chimeric antigen receptor (CAR) T cells is hindered by
'T v T'fratricide against shared antigens such as CD3 and CD7. Base editing offers the …

Successes of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell
therapy in curing patients with otherwise lethal cancers have validated immunotherapy as a …

The field of cancer immunotherapy has rapidly progressed in the past decade as several
therapeutic modalities have entered into the clinic. One such immunotherapy that has shown …

Genetic redirection of T lymphocytes allows us to unleash these potent cellular immune
effectors against cancer. Chimeric antigen receptor (CAR) T cells are the best-in-class …

For many years, the methods of cancer treatment are usually surgery, chemotherapy and
radiation therapy. Although these methods help to improve the condition, most tumors still …

Adoptive cell immunotherapy is a novel tool in the fight against cancer. Serving both effector
and memory functions for the immune system, T cells make an obvious candidate for …